Backing Breakthroughs in Psychedelics

Power to the Patients
06/06/2025 39 min Episodio 5
Backing Breakthroughs in Psychedelics

Listen "Backing Breakthroughs in Psychedelics"

Descargar episodio Ver en sitio original

Episode Synopsis

Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A powerful look at what it takes to bring meaningful change to mental health treatment.

More episodes of the podcast Power to the Patients

One Mechanism, Three Conditions: A New Direction in Neurological Treatment 03/12/2025
Why Traditional Psychedelics Miss 90% of Neurology Patients - And The Solution 12/11/2025
Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo 05/11/2025
Why Clinical Trial Speed Kills Success - And What Top Sponsors Do Instead ft. Steve Brannan 21/10/2025
Dr. Anantha Shekhar on the Convergence of Psychiatry, Neurology, and the Next Era of Brain Medicine 15/10/2025
Ram Mukunda, CEO of IGC Pharma, on Innovation and Hope in Alzheimer’s Care 23/09/2025
Brandon Bentzley, CSO and Co-founder of Magnus Medical, on Precision Psychiatry and Rewiring Depression 17/09/2025
Sarah MacCallum & Melissa Gaines- Clinical Operations Leaders at Annovis Bio 10/09/2025
Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s 05/09/2025
Michael Gold, Chief R&D Officer at Compass Pathways 26/08/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA